[Risks of ovarian overstimulation by administration of clomiphene and gonadotropins for ovulation stimulation].
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D000818:Animals; D006063:Chorionic Gonadotropin / Q000009:adverse effects; D002996:Clomiphene / Q000009:adverse effects*; D004967:Estrogens / Q000652:urine; D005260:Female; D006062:Gonadotropins / Q000009:adverse effects* / Q000652:urine; D006065:Gonadotropins, Pituitary / Q000009:adverse effects; D006801:Humans; D008539:Meigs Syndrome / Q000139:chemically induced*; D010048:Ovarian Cysts / Q000139:chemically induced*; D010060:Ovulation / Q000187:drug effects; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced; D011276:Pregnanediol / Q000652:urine; D012756:Sheep
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D006063:Chorionic Gonadotropin; D004967:Estrogens; D006062:Gonadotropins; D006065:Gonadotropins, Pituitary; D002996:Clomiphene; D011276:Pregnanediol
Gefahren der ovariellen Uberstimulierung bei Anwendung von Clomiphen und Gonadotropinen zur Ovulationsauslösung.